Description (TB500)

Thymosins are small proteins found in many animal tissues. Their name derives from the fact that they were first isolated from the thymus, but they are now known to be distributed throughout numerous parts of the body. Some thymosins—particularly Thymosin α1 and Thymosin β4 —are attracting interest for their potential medical applications, with some already being used clinically.

TB500 is a short peptide (a fragment) related to Thymosin Beta 4 : it is often marketed as if it were the same molecule, but it is not identical to full-length Thymosin Beta 4. In the body, Thymosin Beta 4 can be released from the thymus (more active in pediatric age) and is also produced locally by various cells; it is also found in significant concentrations in certain cellular compartments and in wound-associated secretions. Experimental studies suggest that Thymosin Beta 4 may support various tissue repair processes, promoting cell migration and contributing to the modulation of inflammation.

The TB500 sequence corresponds to the region considered “functionally active” in Thymosin Beta 4 and may share many of its properties, with the advantage of being simpler and cheaper to produce. For this reason, TB500 is often associated with recovery support in the event of tissue stress and injury, with particular interest in the sports world for managing post-workout recovery.

---

Mechanism of action (in summary)

Among the thymosins, Thymosin Beta 4 is one of the most abundant and studied. It is a peptide capable of binding to actin , influencing actin polymerization and thus cell migration —a process important for angiogenesis and tissue regeneration. In several experimental models, Thymosin Beta 4 has also been associated with cardioprotective properties , potential support of angiogenesis under ischemic conditions, and cellular mechanisms related to survival in response to stress.

Still in the experimental setting, effects on:

• repair of damaged tissues and modulation of inflammation

• angiogenesis and regenerative response

• differentiation and migration of cells involved in repair

---

Wound healing and soft tissue

Following injury, Thymosin Beta 4 can be released from platelets, macrophages, and other cells, helping to limit further damage and support repair processes. It has been linked to:

• reduction of apoptosis and inflammation

• support for cell migration and the formation of new vessels

• possible reduction of fibrosis and scarring through modulation of myofibroblasts

In this context, TB500 is often cited as an experimental aid for muscle, tendon, and ligament injuries , especially when inflammation and slow recovery are a concern. It is also mentioned for a possible role in reducing adhesions and tissue stiffness that can limit mobility.

---

View (experimental scope)

In ophthalmology, Thymosin Beta 4 and related peptides have been studied for conditions such as dry eye and neurotrophic keratopathy , with results that, in some settings, have indicated improvements in symptoms and corneal healing.

---

Cardiovascular and nervous system (experimental setting)

Several preclinical studies have explored the use of Thymosin Beta 4 to support:

• regeneration and remodeling of cardiac tissue after ischemia or damage

• angiogenesis in the myocardium and reduction of fibrosis

• protection and recovery in neurological models (e.g. ischemia/stroke)

Clinical data on Thymosin Beta 4 in various settings are also available, but the application, protocols, and final conclusions depend on the indication and the type of formulation studied.

---

Hair (experimental setting)

In animal models, a role for Thymosin Beta 4 in hair follicle biology has been hypothesized, potentially influencing cell migration/differentiation and hair growth cycles. Numerous testimonials circulate online, but they are no substitute for solid clinical evidence.

---

Reported effects (summary)

• Support for the recovery of muscles, tendons, ligaments, skin

• Anti-inflammatory action (in experimental settings)

• Support for angiogenic and repair processes

• Potential interest in skin, cornea, cardiovascular system and CNS (preclinical)

---

Possible side effects

• Redness or pain at the injection site (if used in injectable form)

---

Preparation of the solution (reconstitution)

To reconstitute a freeze-dried powder:

1. Inject the diluent by running the liquid along the wall of the vial (not directly onto the powder).

2. Stir gently until completely dissolved (do not shake).

3. The solution must be clear.

Do not mix different peptides in the same syringe , as this increases the risk of degradation of the molecules.

---

Conservation

After reconstitution, store in the refrigerator at 2–8°C . The solution generally keeps for approximately 21 days ; the shelf life may be increased if bacteriostatic water is used (if provided for by the product).